Assessment of the Increased Risk of Infection Following an Ultratrail

NCT ID: NCT06089174

Last Updated: 2023-10-18

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

1300 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-10-31

Study Completion Date

2023-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The increase in the practice of running has encouraged a proliferation of studies evaluating the impact of this sport on health. A number of these studies have looked at the influence of endurance events on the immune system. After prolonged exercise, a systemic inflammatory syndrome sets in, with repercussions for the functioning of the immune system. The number of lymphocytes in the blood is reduced, the function of natural killer (NK) cells is impaired and secretory immunity is impaired. During this period of immunosuppression, often referred to as the 'open window', the host may be more susceptible to micro-organisms that bypass the first line of defence.

The invetigators' hypothesis is therefore that ultratrailers are overexposed to the risk of infection due to immunodepression resulting from practising this sport. In order to support this hypothesis, the investigators would like to look at infectious complications in general and ear-nose and throat episodes (rhinitis, pharyngitis, laryngitis, etc.) in particular, which are the most common infections encountered in primary care, along with urinary tract infections.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Running Immune Deficiency Infections

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

This study is a descriptive cohort study comparing the occurrence of infection between exposed (runners of an ultra-trail) and unexposed subjects (their companions).
Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Exposed (Runners)

Ultra-endurance runners taking part in an ultra-trail of 72 km, 109 km or 165 km

Group Type EXPERIMENTAL

Ultra-trail

Intervention Type OTHER

Questionnaires sent to runners at various pre-race and post-race times (Day3, Day6, Day10, Day14 and Day21)

Non-exposed (companions)

Runners' companions not running

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Ultra-trail

Questionnaires sent to runners at various pre-race and post-race times (Day3, Day6, Day10, Day14 and Day21)

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* \> 18 years
* Participating in a Grand Raid de la Réunion 2023 race (Mascareignes, Trail de Bourbon, Diagonale des Fous)
* Have a companion living under the same roof during the week preceding the race and the 21 days following the race and who agrees to answer the questionnaires
* Do not object to the research

Exclusion Criteria

* Do not understand French
* A protected adult (guardianship or curatorship) or under court protection
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Jean Monnet University

OTHER

Sponsor Role collaborator

Hôpital Privé de la Loire- Saint Etienne

UNKNOWN

Sponsor Role collaborator

Centre Hospitalier Universitaire de la Réunion

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Nicolas BOUSCAREN, MD

Role: PRINCIPAL_INVESTIGATOR

CHU de la Réunion

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

CHU Réunion

Saint-Denis, , Reunion

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Reunion

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Simon BOSSIS

Role: CONTACT

04 77 42 17 00

Laetitia BERLY, PhD

Role: CONTACT

0262906286

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2023/CHU/23

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Longitudinal Innate Immunity and Aging Study
NCT03944603 ACTIVE_NOT_RECRUITING